GH Fragment 176-191
Also known as: hGH 176-191, AOD9604-related fragment, HGH Frag
GH Fragment 176-191 (also called hGH 176-191 or AOD9604-related fragment) is a GH C-terminal fragment. This is the C-terminal fragment of human growth hormone spanning residues 176 to 191, the region associated with the hormone's effects on fat metabolism.
For research use only.
Key Facts
- CAS
- 66004-57-7
- Molecular Weight (MW)
- ≈1729 g/mol
- Half-life
- Short (minutes–hours; animal PK)
- FDA status
- Not Approved
- Administration Route
- Subcutaneous (research contexts)
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Adipose lipolytic pathways
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected in Dec 2025, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 4
- Listed offers
- 4
- Median price per mg
- $9.00/mg
- Typical $8.50–$10.40/mg
Research summary
C-terminal fragment of human GH studied for lipolysis. Closely related to AOD-9604. Not FDA-approved. WADA S2 (GH fragments).
Peptide Library's GH Fragment 176-191 profile summarises 2 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Not established for human therapy
- Frequency
- —
- Cycle
- —
- Administration Route
- Subcutaneous (research contexts)
- Reconstitution Guide
- —
- Timing Notes
- Studied for lipolytic signaling; not approved.
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. GH Fragment 176-191 is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C78H123N23O23S2 |
|---|---|
| Molecular weight | ≈1729 g/mol |
| CAS number | 66004-57-7 |
| Half-life | Short (minutes–hours; animal PK) |
| Appearance | White lyophilized powder (acetate) |
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
This is the C-terminal fragment of human growth hormone spanning residues 176 to 191, the region associated with the hormone's effects on fat metabolism. The rationale for isolating it is that the growth-promoting and insulin-antagonising actions of growth hormone are mediated through receptor-driven JAK2/STAT5 signalling and hepatic IGF-1 production, whereas the lipolytic effect was thought to be separable. In rodent adipocyte studies the fragment increased lipolysis and reduced lipogenesis without raising IGF-1. Human evidence for meaningful fat loss is weak, and the fragment does not reproduce the anabolic effects of intact growth hormone.
Origin
Synthetic fragment of human growth hormone.
Targets
Studies
Regulatory & research status
GH Fragment 176-191 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Research-Only |
Benefits
GH Fragment 176-191 side effects
Side Effects
- Injection reactions
- Uncertain efficacy
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
GH Fragment 176-191: frequently asked questions
What is GH Fragment 176-191?
C-terminal fragment of human GH studied for lipolysis. Closely related to AOD-9604. Not FDA-approved. WADA S2 (GH fragments).
How does GH Fragment 176-191 work?
This is the C-terminal fragment of human growth hormone spanning residues 176 to 191, the region associated with the hormone's effects on fat metabolism. The rationale for isolating it is that the growth-promoting and insulin-antagonising actions of growth hormone are mediated through receptor-driven JAK2/STAT5 signalling and hepatic IGF-1 production, whereas the lipolytic effect was thought to be separable.
Is GH Fragment 176-191 FDA approved?
No. GH Fragment 176-191 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of GH Fragment 176-191?
Reported half-life for GH Fragment 176-191 is Short (minutes–hours; animal PK). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is GH Fragment 176-191 banned in sport?
GH Fragment 176-191 is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to GH Fragment 176-191?
Compounds most often compared with GH Fragment 176-191 include AOD-9604, Human Growth Hormone (Somatropin), 5-Amino-1MQ and Adipotide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- WADA Prohibited List 2026External reference
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — Front Endocrinol (Lausanne), 2026External reference
- Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices — Analyst, 2026External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This GH Fragment 176-191 profile is compiled from published literature (2 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track GH Fragment 176-191 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →